Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Conditions
Interventions
SD-809
Placebo
Locations
41
United States
Tuscaloosa, Alabama, United States
Anaheim, California, United States
Glendale, California, United States
Oceanside, California, United States
Orange, California, United States
San Bernardino, California, United States
Start Date
June 1, 2014
Primary Completion Date
May 1, 2015
Completion Date
May 1, 2015
Last Updated
November 9, 2021
NCT06997198
NCT05859698
NCT05238701
NCT02198794
NCT02291861
NCT02064010
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions